Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)
Associations between extent of fibrotic interstitial lung disease (ILD) and forced vital capacity (FVC) at baseline and change in FVC in subjects with systemic sclerosis-associated ILD (SSc-ILD) in the SENSCIS trial
Denton CP et al.
Effect of nintedanib on decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) by GAP stage and ILD-GAP index
Kreuter M et al.
Decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without cough: data from the SENSCIS trial
Kreuter M et al.
Impact of forced vital capacity decline on hospitalization events in systemic sclerosis-associated interstitial lung disease: a joint model analysis using data from the SENSCIS trial
Kreuter M et al.
Correlations between changes in FVC and imaging parameters in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD): sub-study of the SENSCIS trial
Humphries SM et al.
Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD): data from the SENSCIS-ON trial
Highland KB et al.
